Latest news and press releases about Ovid Therapeutics Inc. (OVID): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infa...
Price
| Price | $2.68 |
| Market Cap | $500M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.96 |
| EV / EBITDA | -14.12 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -23.64% |
| Return on Invested Capital | -26.11% |
| Return on Assets | -14.87% |
| Gross Margin | 100.00% |
| Operating Margin | -3686.67% |
| Net Margin | -2178.90% |
Related companies: CLNN · CNTB · CNTX · IFRX · IMA · KLRS · MGNX
Explore sector: Healthcare · Biotechnology
More sections of OVID: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks